Hong Kong Third-Generation IVF: From Genetic Disease Screening to Chromosomal Health Management

When a family has a history of single-gene genetic disorders such as albinism, thalassemia, or congenital hearing loss, natural conception may involve uncertainty regarding inherited risks. For couples carrying known disease-causing genes, each pregnancy may carry the possibility of passing genetic conditions to their children.

With advances in reproductive medicine, Preimplantation Genetic Testing for Monogenic Disorders (PGT-M), an important application of third-generation IVF technology, provides these families with a new reproductive option. After embryos are created through in vitro fertilization, genetic testing can be performed before embryo transfer to identify whether embryos carry specific disease-related mutations and help doctors select suitable embryos.

This technology does not alter genes or create “designer babies.” Instead, it provides an opportunity for early genetic assessment, allowing families with known genetic risks to make more informed reproductive decisions.

Single-Gene Genetic Disorders: Why Early Genetic Assessment Matters

Not all genetic diseases appear immediately after birth. Some conditions may remain hidden for years and can only be identified through family history or genetic testing.

Common single-gene disorders include:

• Thalassemia;

• Albinism;

• Cystic fibrosis;

• Certain inherited hearing disorders;

• Some metabolic diseases.

These conditions are usually caused by abnormalities in a specific gene. When both parents carry disease-related mutations, their children may face an increased risk of inheriting the condition.

During natural conception, families often discover genetic risks through prenatal testing after pregnancy occurs. For couples with known genetic concerns, third-generation IVF provides an earlier opportunity to evaluate embryos before pregnancy begins.

PGT-M: Genetic Assessment Before Embryo Transfer

Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) is designed specifically for single-gene genetic diseases.

The general process includes:

1. Ovarian stimulation and egg retrieval;

2. Fertilization of eggs and sperm in a laboratory;

3. Embryo culture to an appropriate testing stage;

4. Genetic analysis of embryo cells;

5. Transfer of embryos without detected disease-causing mutations when medically appropriate.

Simply put, PGT-M works like a “genetic health review” before embryo transfer.

It does not modify embryo genes and does not create genetically selected individuals. Instead, it helps doctors identify embryos with lower genetic disease risk among available embryos and develop a more precise treatment strategy.

For families where both partners carry genetic risks, such as thalassemia-related mutations, PGT-M may help reduce the chance of passing the condition to future children.

Third-Generation IVF in Hong Kong: Increasing Attention Toward Genetic Health

As one of Asia’s major medical centers, Hong Kong has developed a relatively advanced healthcare system in assisted reproduction and genetic medicine.

With growing awareness of genetic health, more families are exploring third-generation IVF technologies to evaluate potential reproductive risks before pregnancy.

In Hong Kong fertility care, doctors generally conduct comprehensive assessments considering:

• Family history of genetic diseases;

• Genetic testing results of both partners;

• Female age and ovarian function;

• Embryo development outcomes;

• Previous pregnancy history.

For families with clear genetic risks, targeted embryo genetic testing may be recommended to improve reproductive planning.

Chromosomal Abnormalities: A Major Cause of Recurrent Pregnancy Loss

Besides single-gene disorders, chromosomal abnormalities are another important factor affecting embryo development.

Normally, humans have 23 pairs of chromosomes. When chromosome numbers or structures become abnormal, embryo development may be affected.

Chromosomal abnormalities may contribute to:

• Failure of embryos to continue developing;

• Early miscarriage;

• Recurrent pregnancy loss;

• Repeated IVF implantation failure.

For women of advanced maternal age, changes in egg quality may increase the likelihood of chromosomal abnormalities, making chromosome assessment an important consideration in some assisted reproductive treatment plans.

PGT-A: A “Chromosome Health Check” for Embryos

For risks related to chromosome number abnormalities, doctors may consider Preimplantation Genetic Testing for Aneuploidy (PGT-A).

PGT-A evaluates whether embryos have abnormal chromosome numbers, including missing or extra chromosomes.

Through this assessment, doctors can better understand embryo chromosomal status and, when medically appropriate, prioritize embryos with a normal chromosome number (euploid embryos) for transfer.

This process is similar to giving embryos a “chromosome health check” before implantation, helping improve the opportunity to select embryos with better developmental potential.

PGT-A may be considered for individuals including:

• Women of advanced reproductive age;

• Patients with recurrent miscarriage;

• Individuals with repeated IVF implantation failures;

• Those with previous pregnancies affected by chromosomal abnormalities.

Genetic Testing Supports Better Planning, Not Guaranteed Outcomes

It is important to understand that both PGT-M and PGT-A are risk management tools within assisted reproduction. They cannot guarantee pregnancy success or completely eliminate all risks of genetic or medical conditions.

Embryo testing results must be interpreted together with medical evaluation, pregnancy monitoring, and long-term health management.

However, for families facing genetic risks or repeated reproductive challenges, these technologies provide a more proactive approach to fertility planning.

In the past, many families could only discover potential risks after pregnancy occurred. Today, advances in reproductive medicine allow certain genetic information to be assessed at the embryo stage, providing more scientific guidance for future decisions.

From Genetic Disease Prevention to Chromosomal Health Management: Hong Kong Enters an Era of Precision Reproduction

From PGT-M for single-gene disorders to PGT-A for chromosomal abnormalities, third-generation IVF technology is helping reproductive medicine move beyond simply achieving pregnancy toward more precise fertility planning.

For families with genetic disease histories, recurrent miscarriage, or advanced maternal age concerns, early consultation and professional assessment can help create more suitable reproductive strategies.

Modern reproductive medicine is not about selecting life, but about reducing avoidable genetic risks within medical and ethical boundaries, giving more families the opportunity to welcome healthy children.